Zenocutuzumab offers meaningful and durable antitumor activity, substantially
reduced toxicity and no treatment‑limiting safety concerns, distinguishing it favorably
 from existing standards of care

LEXINGTON, Mass.  – July 2, 2026 – Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, announced that results from the cholangiocarcinoma cohort of the eNRGy trial (NCT02912949) have been published in the Journal of Clinical Oncology (JCO).¹ These data supported the recent U.S. Food and Drug Administration (FDA) approval of BIZENGRI^® (zenocutuzumab-zbco) for the treatment ...